Previous 10 | Next 10 |
ST. LOUIS, May 23, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the first treatment of patients with a newly launched Genesis Robotic Magnetic Navigation (RMN) system at Advocate Christ Medic...
2023-05-19 12:57:00 ET This week was a milestone week for the stock market. The S&P 500 ( NYSE: SPY ) and Nasdaq ( NASDAQ: QQQ ) put in fresh 2023 highs. What could be more impressive is while terms like “stock market crash” and “recession” are trendi...
2023-05-19 10:04:48 ET Gainers: Lucy Scientific Discovery ( LSDI ) +51% . Bioventus ( BVS ) +44% . Mallinckrodt ( MNK ) +28% . 180 Life Sciences ( ATNF ) +28% . Stereotaxis ( STXS ) +25% . Losers: Enveric Biosciences ( ENVB ...
2023-05-19 09:20:40 ET Stereotaxis ( NYSE: STXS ) is collaborating with Abbott Laboratories ( NYSE: ABT ) to combine mapping and robotic technologies to improve treatment of abnormal heart rhythms. The partnership will integrate Abbott's EnSite X EP Syst...
ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems. The combination of Abbott’s ...
2023-05-09 17:58:04 ET Stereotaxis, Inc. (STXS) Q1 2023 Earnings Conference Call May 09, 2023 10:00 AM ET Company Participants David Fischel - CEO & Chairman Kimberly Peery - CFO & Secretary Conference Call Participants Joshua Jennings - TD Cowen ...
2023-05-09 09:20:44 ET Stereotaxis press release ( NYSE: STXS ): Q1 GAAP EPS of -$0.07 misses by $0.01 . Revenue of $6.55M (-7.0% Y/Y) misses by $0.08M . Gross margin for the first quarter of 2023 was 59% of revenue. Recurring revenue gross margin was 79% and s...
ST. LOUIS, May 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2023. “Stereotaxis continues to make sig...
2023-05-08 13:04:32 ET Stereotaxis ( NYSE: STXS ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is -$0.06 (flat Y/Y) and the consensus Revenue Estimate is $6.63M (-5.3% Y/Y). Over the last 1 year, STXS ...
ST. LOUIS, April 18, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 first quarter on Tuesday, May 9, 2023 before the open ...
News, Short Squeeze, Breakout and More Instantly...
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Gene...
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation...
ST. LOUIS, May 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac ...